Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide (Q50864223)

24 March 2018

http://europepmc.org/abstract/MED/28639485

title

Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide (English)

1 reference

24 March 2018

http://europepmc.org/abstract/MED/28639485

main subject

lymphocyte

0 references

chronic lymphocytic leukemia

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Giuseppe Alberto Palumbo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Gianluca Gaidano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Davide Rossi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Rossana Maffei

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Stefania Fiorcari

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Silvia Martinelli

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Stefania Benatti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Lara Rizzotto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Giulia Debbia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Rita Santachiara

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Gian Matteo Rigolin

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Francesco Forconi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Luca Laurenti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Daniele Vallisa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Antonio Cuneo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Roberto Marasca

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

22 June 2017

1 reference

24 March 2018

http://europepmc.org/abstract/MED/28639485

published in

Leukemia & Lymphoma

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

423-433

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

The microenvironment in mature B-cell malignancies: a target for new treatment strategies

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Lenalidomide in chronic lymphocytic leukemia: the present and future in the era of tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

How does lenalidomide target the chronic lymphocytic leukemia microenvironment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Activation of the Wnt signaling pathway in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Small molecule inhibitors of Wnt/beta-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Shisa promotes head formation through the inhibition of receptor protein maturation for the caudalizing factors, Wnt and FGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Shisa3 is associated with prolonged survival through promoting β-catenin degradation in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428194.2017.1339872

10.1080/10428194.2017.1339872

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28639485%20AND%20SRC:MED&resulttype=core&format=json